

1 **Gene expression levels of the glycolytic enzymes lactate dehydrogenase A**
2 **(LDHA) and phosphofructokinase platelet (PFKP) are good predictors of**
3 **survival time, recurrence and risk of death in cervical cancer.**

4
5 Verónica Bolaños-Suárez¹, Ana Alfaro², Ana María Espinosa³, Ingrid Medina-
6 Martínez⁴, Eligia Juárez⁵, Nicolás Villegas-Sepúlveda⁶, Marco Gudiño-Zayas¹,
7 América Gutiérrez-Castro⁵, Edgar Román-Bassaure⁷, María Eugenia Salinas-
8 Nieves⁸, Sergio Bruno-Muñoz⁸, Oscar Flores-Herrera⁹, Jaime Berumen^{1*}.

9
10 1.Unidad de Investigación en Medicina Experimental, Facultad de Medicina,
11 Universidad Nacional Autónoma de México, Mexico City, Mexico

12 2.Anatomía Patológica. Hospital General de México, Dr. Eduardo Liceaga,
13 Mexico City, México.

14 3.Farmacología Clínica, Hospital General de México, Dr. Eduardo Liceaga,
15 Mexico City, México.

16 4.Departamento de Bioquímica y Biología Molecular, Facultad de Medicina,
17 Universidad Nacional Autónoma de México, Mexico City, México.

18 5.Unidad de Medicina Genómica, Hospital General de México. Dr. Eduardo
19 Liceaga Mexico City, México.

20 6.Departamento de Biomedicina Molecular, Centro de Investigación y Estudios
21 Avanzados del Instituto Politécnico Nacional, Mexico City, México.

22 7.Servicio de Oncología, Hospital General de México, Dr. Eduardo Liceaga,
23 Mexico City, México.

24 8.Servicio de Ginecología, Clínica de Colposcopia, Hospital General de
25 México, Dr. Eduardo Liceaga, Mexico City, México.

26 9.Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional
27 Autónoma de México, Mexico City, México.

28
29 ***Corresponding author:** Unidad de Investigación en Medicina Experimental,
30 Facultad de Medicina, UNAM, Hospital General de México Dr. Eduardo Liceaga,
31 06720, Mexico City, Mexico, phone: +52 551850-4023.

32 **e-mail:** *jaimeberumen47@gmail.com*.

33
34
35 **Keywords:** *Lactate dehydrogenase A (LDHA), phosphofructokinase platelet (PFKP),*
36 *cervical cancer, survival, risk of death.*

Abstract

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63

Background. Up to 74% of patients with cervical cancer (CC) may experience recurrence after their treatment, and most of them are identified late when only the clinical parameters are used, which decreases their chances of recovery. Molecular markers can improve the prediction of clinical outcome and identify therapeutic targets in CC. Glycolysis is altered in 70% of CCs, so it could be a metabolic pathway in which molecular markers associated with the aggressiveness of CC can be identified.

Methods. The expression of 14 glycolytic genes was analyzed in 118 CC samples by microarrays, and only LDHA and PFKP were validated by qRT-PCR (n=58) and in second and third replicates by Western blotting (n=69) and immunohistochemistry (n=18).

Results. LDHA and PFKP were associated with poor overall survival [OS: LDHA HR=3.0 (95% CI= 1.1-8.2); $p=2.9 \times 10^{-2}$; PFKP HR=3.4 (95% CI= 1.1-10.5); $p=3.5 \times 10^{-2}$] and disease-free survival [DFS: LDHA HR=2.7 (95% CI= 1.6-6.3); $p=2.6 \times 10^{-2}$] independent of FIGO clinical stage. The risk of death was greater when both biomarkers were overexpressed than when using only FIGO stage [HR =7 (95% CI 1.6-31.1, $p=1.0 \times 10^{-2}$) versus HR=8.1 (95% CI=2.6-26.1; $p=4.3 \times 10^{-4}$)] and increased exponentially as the expression of LDHA and PFKP increased.

Conclusions. LDHA and PFKP at the mRNA and protein levels were associated with poor overall survival, disease-free survival and increased risk of death of patients with CC regardless of FIGO stage. The measurement of expression of these two markers could be very useful to evaluate the clinical evolution and the risk of death from CC and to make better therapeutic decisions at the beginning of treatment.

65 **1. Background**

66 Cervical cancer (CC) is the fourth most common cancer in women worldwide [1]
67 Persistent infection with human papillomavirus (HPV), particularly high-risk oncogenic
68 viruses, is the main etiological agent for the development of CC. Despite early
69 detection programs and vaccinations against the most oncogenic HPVs [2], it is
70 estimated that 569,000 new cases occur each year and cause 311,365 deaths
71 worldwide [1], indicating that CC continues to be a major health problem, mainly in
72 developing countries where most cases occur.

73 Treatment of CC includes surgery, radiotherapy and chemotherapy, which depend on
74 the clinical stage of the disease [3]. However, it is estimated that a significant
75 percentage of patients have pelvic recurrence (10-23% in stage IB-IIB and 42-74% in
76 stage III-IVA) or metastases (16-26% in stage IB-IIB and 39-75% in stage III-IVA)
77 after treatment, and when this occurs, the patients often have poor survival [4] , [5]. In
78 addition, only 32% of patients with recurrent disease are identified early (before 6
79 months) during medical follow-up, which decreases the chance of recovery and the
80 survival time [6]. Although the clinical International Federation of Gynecology and
81 Obstetrics (FIGO) stage, the clinical characteristics of the tumor, metastasis to lymph
82 nodes and parametrial invasion are predictors of recurrence and survival time, there
83 are no molecular markers approved for clinical use that predict the clinical evolution
84 of patients with CC. Molecular markers alone or in conjunction with clinical data
85 improve the prediction of the clinical outcome and facilitate better therapeutic
86 decision-making, as has been demonstrated in colorectal [7] and breast [8] cancers.

87 Since glycolysis is increased in 70% of human cancers, with lactate production even
88 in the presence of oxygen (Warburg effect) [9][10], it can be used to identify new

89 prognostic biomarkers in CC. In fact, the usefulness of several genes or proteins
90 involved in glycolysis has been investigated to evaluate survival and aggressiveness
91 in CC, such as glucose transporter 1 (GLUT1) [11], hexokinase 2 (HK2) [12],
92 phosphofructokinase isoform M (PFKM) (as part of a genetic profile)[13] and total
93 lesion glycolysis (TLG), a parameter measurable through positron emission
94 tomography (PET) [14]. However, the predictive efficacy of these biomarkers either
95 has not been reported or has been reported to be intermediate. Perhaps PET is the
96 most efficient method; however, it is very expensive. On the other hand, it would be
97 desirable to identify molecular therapeutic targets in CC since the antitumor strategy
98 with specific target drugs is showing great benefit in many tumor types with a marked
99 decrease in side effects [15].

100 In a previous study, our group found a glycolytic gene profile in CC associated with a
101 decrease in survival [16]. In this paper, we investigate which genes of that glycolytic
102 expression profile are most highly associated with survival and tumor aggression in
103 CC. Of the genes finally identified, the mRNA and protein levels of lactate
104 dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) were explored in
105 a main discovery sample of 118 CCs, and they were validated in two additional
106 replicates (n = 58 and 69 CCs) and in 18 CC tissues preserved in paraffin. These two
107 markers allow to evaluate of the clinical evolution and mortality of patients with CC
108 regardless of the FIGO stage.

109 **2. Materials**

110 **Ethical consent**

111 The study protocol was approved by the Scientific and Ethics Committee of the
112 General Hospital of Mexico (HGM) (approval number DIC/03/311/04/051). This study,
113 all experiments and analyses were performed in accordance with the Declaration of

114 Helsinki [17]. Written informed consent was obtained from all participants before their
115 inclusion in the study.

116 **Patient selection and clinical characteristics**

117 The study included 188 patients with CC (Supplementary Figure 1, Supplementary
118 Table 1), 10 patients with high-grade epithelial lesions (HG-CINs) and 36 women with
119 healthy cervical epithelium (HCE) evaluated in the Departments of Oncology and
120 Gynecology and Obstetrics of the HGM. Patients with CC were selected from a
121 previous study that included 462 patients recruited from November 2003 to April
122 2005 and from January 2006 to July 2007 [18]. The inclusion criteria were as follows:
123 patients diagnosed with invasive CC, without previous treatments. Only patients from
124 whom high-quality RNA and tumor biopsies had more than 70% tumor cells were
125 included in the present study. The exclusion criteria were insufficient quality of the
126 biological sample. All patients received complete clinical evaluation and were treated
127 with surgery, radiation, chemotherapy, or a combination of these according to
128 American Cancer Society guidelines. Tumor staging was performed in accordance
129 with the latest International Federation of Gynecology and Obstetrics (FIGO) protocol
130 for gynecological cancer [19]. The average age of the patients was 51 years, with a
131 range of 23 to 89 years. After their treatment, they were followed up and evaluated
132 periodically at the HGM. HCE were obtained from patients who underwent
133 hysterectomy for myomatosis with a normal cervix for cytology and colposcopy as
134 described previously [18]. The tissues were frozen in liquid nitrogen and stored at -
135 80°C.

136 **RNA isolation**

137 Total RNA from the samples was extracted with TRIzol™ reagent (Invitrogen,
138 Carlsbad CA, USA) according to the manufacturer's instructions. RNA integrity was

139 verified by agarose gel electrophoresis, determining the presence of 18S and 28S
140 ribosomal RNA.

141

142 **Glycolytic gene expression and data analysis**

143 The glycolysis gene expression of 76 CC, 10 HG-CIN and 17 HCE tissues was
144 examined using a Human Gene 1.0ST (HG-1.0ST) microarray and with the Human
145 Gene Focus (HG-Focus) microarray in 42 CCs and 12 HCE (Affymetrix, Santa Clara,
146 CA). Gene expression was obtained from two studies previously published by our
147 working group in the Gene Expression Omnibus (GEO) database with accession
148 numbers GSE52904 [16] and GSE39001 [18]. See supplementary text 1.

149 **Quantitative PCR (qRT-PCR)**

150 cDNA was synthesized using the High-Capacity cDNA Transcription Kit (Applied
151 Biosystems) using 5 µg of RNA according to the manufacturer's protocol. Gene
152 expression of *LDHA*, *PFKP* and an internal control (*RPS13*) was measured in 58 CC
153 and 19 HCE by qRT-PCR and TaqMan gene expression assays were used (*LDHA*,
154 Hs00855332_g1; *PFKP*, Hs00242993_m1; *RPS13*, HS 01011487_g1; Applied
155 Biosystem Inc.). The experiments were run in triplicate in a final volume of 20 µL,
156 including 200 ng of cDNA template using the TaqMan® Universal PCR Master Mix
157 (4304437, Applied Biosystems), according to the manufacturer's instructions. The
158 expression of the *LDHA* and *PFKP* genes was normalized in each tumor and control
159 sample with *RPS13* using as previously reported [18]. The FC in expression was
160 calculated by dividing the median normalized intensity of each tumor sample by the
161 median normalized intensity of the whole control samples.

162 **Western blot (WB)**

163 *LDHA* and *PFKP* protein expression was determined using WB in 69 CC samples.
164 25 ng of protein was resolved on 8% SDS-PAGE and electrotransferred onto a

165 nitrocellulose membrane and incubated with a mouse monoclonal antibodies anti-
166 human LDHA (H-10: sc-133123; 1:1,000) or PFKP (F-7: sc-514824; 1:200) and goat
167 β -actin antibody (I-19: sc-1616), (Santa Cruz Biotechnology, Inc.) overnight at 4°C.
168 The membranes were then incubated with horseradish peroxidase (HRP)-conjugated
169 secondary antibodies (anti-mouse IgG + IgM (H+L) antibodies; 1:10,00; Jackson
170 ImmunoResearch Laboratories, Inc.) and anti-goat IgG-HRP (sc-2354; 1:1,000;
171 Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. Prestained Broad
172 Range SDS-PAGE Standards (BIO-RAD, CA) were used for molecular weight
173 estimation on gels. β -actin was used as an internal control. Loading buffer without
174 sample was used as negative control. The immunoreactive proteins were developed
175 using the SuperSignal™ Chemiluminescent HRP Kit (Thermo Fisher Scientific).
176 Densitometric analysis was performed with ImageJ (NIH, Bethesda, MD). The optical
177 density was calculated as $OD = \log_{10}(255/\text{pixel value})$.

178 **Immunohistochemistry (IH)**

179 The protein expression of LDHA and PFKP was determined in 18 CC, 12 HCE and 6
180 metastatic samples by IH. Human paraffin-embedded tissue samples were collected
181 at the Pathology Department of HGM from patients evaluated from January 2008 to
182 March 2013. The inclusion criteria were women with CC at any FIGO stage whose
183 diagnostic biopsy was taken prior to treatment, with complete clinical data available,
184 and with follow-up data of at least 24 months after treatment. All patients received
185 complete clinical evaluation according to the ACS guidelines. Clinicopathological
186 information was collected from medical records. Tissue microarrays (TMAs) were
187 built as previously described [18]. The TMA included kidney tumor tissue as a
188 positive control, which was previously determined to present high LDHA and PFKP
189 expression (www.proteinatlas.org). IH was performed with the Ultra Streptavidin
190 (USA) HRP Detection Kit (Multi-Species) (BioLegend, CA) according to the

191 manufacturer's instructions. The following mouse monoclonal antibodies were used:
192 LDH (H-10) sc-133123 (1:200) and PFKP (F-7) sc-514824 (1:100) from Santa Cruz
193 Biotechnology (Santa Cruz, CA). Antigen-antibody complexes were detected using
194 the avidin-biotin peroxidase method, with 3,3'-diaminobenzidine-tetrahydrochloride as
195 a chromogenic substrate (DAB Chromogen Concentrate, BioLegend, CA), and the
196 sections were counterstained with hematoxylin. Assays were performed in triplicate.

197 **Quantitative image analysis**

198 Each tissue of the TMA was photographed in triplicate with a magnification of 400X
199 using a Nikon Microphot FXA. The digital images were analyzed with ImageJ as
200 previously described [20] and the intensity of DAB signal was transformed to optical
201 density values: $OD = -\log(255 * \text{maximum level pixels} / \text{average pixels})$. The integrated
202 optical density (DOI) was calculated as $OD \times \text{staining area}$.

203 **Survival analysis**

204 After the treatment was completed, each patient was clinically evaluated every 3 or 6
205 months by an experienced oncologist. Clinical data of the follow-up study were
206 obtained from the patient's medical record. Additionally, a social worker performed
207 phone calls and home visits to the patients every 6 months during the study. Survival
208 analysis was performed on all patients who received the full treatment. The mean
209 follow-up time was 60 months after the initial diagnosis. The patients designated as
210 censored referred to patients who were lost to follow-up or who died from causes
211 other than CC. Patients were considered lost when they did not attend medical
212 appointments for disease control, were not found at home visits or did not answer
213 phone calls. In this cohort, alive status was registered at the last follow-up, and death
214 was caused by a primary tumor of CC as a main cause and confirmed by the medical
215 record and the death certificate.

216 **Statistical analysis**

217 Data analysis was performed using SPSS software ver. 20. Receiver operating
218 characteristic (ROC) curve analysis was performed, and the Youden index was used
219 [21] to select the best cutoff points to distinguish tumors from nonsurviving and
220 surviving patients or patients who survived with and without the disease using the
221 expression values of glycolysis genes obtained by microarrays, qRT-PCR and WB.
222 Expression values equal to or above the cutoff were considered upregulated, and
223 those with values below the cutoff were considered downregulated.

224 The comparisons of the overall survival (OS) and disease-free survival (DFS) times
225 between patients with upregulated and downregulated tumor genes were calculated
226 by the Kaplan-Meier method and analyzed by the log-rank test. FIGO staging and
227 glycolysis gene expression were included in univariate and multivariable Cox
228 proportional hazards regression models. All tests were 2-sided, and p values less
229 than 0.05 were considered statistically significant.

230 **3. Results**

231 **Analysis of glycolytic gene expression in CC**

232 The expression of genes involved in glycolysis included in the HG-1.0ST microarray
233 was analyzed in 103 cervical samples, including 76 CC, 10 HG-CINs and 17 HCE. As
234 shown in Supplementary Figure 2, the 14 genes had significantly higher expression
235 levels in the invading CCs than in the controls. Interestingly, we were able to confirm
236 the difference between the invading cancers and the control group for 9 of these
237 genes (SLC2A1, HK2, PFKP, ALDOA, GAPDH, PGK1, ENO, PKM and LDHA) in a
238 second replicate with 42 invasive CCs and 12 controls, explored with a second
239 microarray (HG-Focus; see Supplementary Figure 3), which included only 9 of the 14
240 formerly explored genes. The samples were distributed into 3 groups, according to
241 the expression profile, in the hierarchical clustering analysis: upregulation (group 3);
242 intermediate regulation (group 2), which could be divided into the intermediate
243 downregulation subgroup (group 2A) and the high intermediate upregulation

244 subgroup (group 2B); and downregulation (group 1). Group 3, in which most genes
245 were overexpressed in all samples, was composed only of CC (n=28) and the 3 CC-
246 derived cell lines (HeLa, SiHa and CaSki). In contrast, in group 1, in which the
247 glycolysis genes were not overexpressed, almost all controls were found (n=13,
248 76.5%), along with 4 of the 10 HG-CINs and a group of 15 CCs (19.7%). Group 2B,
249 like group 3, was composed only of CC, while group 2A, more like group 1, was
250 composed of HCE, HG-CINs and CCs (Figure 1, Supplementary Table 2). In the
251 hierarchical grouping with the samples explored with HG-Focus, the distribution of
252 the CCs and controls was very similar to the distribution obtained with the HG-1.0ST
253 data (Supplementary Figure 4, Supplementary Table 2). Interestingly, the frequency
254 of CCs with the highest clinical stage (\geq stage IIIA) predominated in group 3 (58.4%),
255 while those with lower clinical stages (\leq stage IIB) were distributed uniformly among
256 the 4 groups ($p=5.0 \times 10^{-2}$, chi-square test) (Supplementary Table 2).

257 **Effect of the gene expression of the 14 glycolysis genes on survival**

258 Interestingly, the expression profile of the 14 genes explored significantly influences
259 the survival of patients with CC. Almost all women with CC (95%) whose tumors did
260 not overexpress glycolysis genes (groups 1 and 2A) survived more than 5 years. In
261 contrast, only 55% of patients with CC who had a glycolysis overexpression profile
262 (groups 2B and 3) survived more than 5 years (Supplementary Figure 5A), although
263 the difference between the two groups presented marginal statistical significance ($p=$
264 5.0×10^{-2} , log-rank test). To investigate which genes, contribute most significantly to
265 that profile, survival was analyzed separately for each gene. Of the 14 genes
266 identified with the HG-1.0ST microarray, the overexpression of only 8 of them
267 (GAPDH, PGK1, TPI1P1, LDHA, ALDO, PFKP, ENO, and GPI) significantly reduced
268 the % OS of the patients, with p values ranging from $p=1.0 \times 10^{-4}$ to $p=1.3 \times 10^{-2}$ in
269 the log-rank test (Supplementary Figure 5B, C, D, E, F, G, H, and I). In addition, 5 of

270 them (GPI, PFKP, TPI1P1, GAPDH, and LDHA) were also associated with a
271 significant reduction in % DFS (Supplementary Figure 5J-O). Of the 9 genes explored
272 with HG-Focus, the gene expression levels of only 3 of them (ALDO, PGK1 and
273 LDHA) were also significantly associated with the reduction in % OS ($p = 3.3 \times 10^{-2}$, p
274 $= 9.0 \times 10^{-3}$, and $p = 5.0 \times 10^{-2}$, respectively, log-rank test), and only 1 (LDHA; $p = 3.0$
275 $\times 10^{-2}$, log-rank test) was also associated with DFS (see Supplementary Figure 6).

276 To determine whether the overexpression of these genes is independent of clinical
277 stage, both variables were analyzed in a multivariate Cox proportional hazards
278 model. Due to the small number of patients (n=61), they were grouped into two
279 clinical groups, group 1 (\leq stage IIA, n=29) and group 2 (\geq stage IIB, n=32).
280 Univariate analysis showed that the risk of death (hazard ratio, HR) of patients in
281 group 2 was 3.4 (95% confidence interval (CI) = 1.1-10.4; $p = 3.6 \times 10^{-2}$, Cox test;
282 Table 1) times higher than that of patients in group 1. As expected, the
283 overexpression of 7 of the 8 genes conferred an increased risk of death, ranging from
284 an HR of 2.8 (95% CI 1.0-7.6; $p = 3.7 \times 10^{-2}$) for the PGK1 gene to an HR of 9.2
285 (95% CI = 1.2-69.5; $p = 3.7 \times 10^{-2}$) for the ENO1 gene (see Table 1).

286 However, when explored in conjunction with FIGO stage in multivariate analysis, only
287 the LDHA gene with an HR of 3.0 (95% CI =1.1-8.2; $p = 2.9 \times 10^{-2}$), the PFKP gene
288 with an HR of 3.4 (95% CI = 1.1-10.5; $p = 3.5 \times 10^{-2}$) and the pseudogene TPI1P1
289 with an HR of 2.6 (95% CI = 1.0-7.9; $p = 4.0 \times 10^{-2}$) conferred an increased risk of
290 death, regardless of the FIGO clinical stage (Table 1). When DFS was analyzed, only
291 LDHA with an HR of 2.7 (95% CI = 1.1-6.2; $p = 2.9 \times 10^{-2}$) was independent of FIGO
292 stage (Supplementary Table 3). LDHA experimental findings were also confirmed
293 with the HG-Focus data (see Supplementary Tables 4 and 5).

294 **Validation of LDHA and PFKP expression at the mRNA and protein levels**

295 The gene expression of the LDHA and PFKP genes was validated by qRT-PCR,
296 WB, and IH. qRT-PCR confirmed that the expression of both genes was higher in the
297 invading CCs (n=58) than in the HCE (n=19) However, the difference was much
298 greater for the LDHA (FC=100.3; $p=9.8 \times 10^{-8}$, Mann-Whitney test) than for PFKP
299 gene (FC=4.3, $p=2.0 \times 10^{-6}$, Mann-Whitney test, Figure 2A). Interestingly, we found
300 that the expression levels of LDHA and PFKP were in average 1.6 and 1.7 times
301 higher, respectively, in patients who died and/or presented active disease
302 (recurrence) than in those who survived and were cured ($p=9.0 \times 10^{-3}$ to $p=2.8 \times 10^{-2}$;
303 Mann-Whitney test, see Supplementary Table 6).

304 In addition, we confirmed the presence of the LDHA and PFKP proteins by WB in 69
305 CC samples (15 of the 58 tumors explored for RNAs by qRT-PCR and 54 new CCs).
306 LDHA and PFKP proteins were expressed at higher levels in the tumors of patients
307 who did not survive (FC=14.9, $p=3.0 \times 10^{-3}$ and FC=21.4, $p=1.8 \times 10^{-3}$, respectively;
308 Mann-Whitney test) or who survived with the disease (FC=29.1, $p=1.4 \times 10^{-4}$ and
309 FC=17.2, $p=1.7 \times 10^{-3}$, respectively; Mann-Whitney test, Figure 2B-D) compared to
310 tumors of patients who survived or disease-free survival more than 5 years.

311 Additionally, we analyzed the expression of these glycolytic enzymes by IH in HCE
312 tissues (n=12), CC tissues (n=18) and metastatic tissues (n=6) preserved in paraffin
313 from a new group of patients. LDHA and PFKP expression levels were significantly
314 higher in tumor tissues than in HCE tissues (FC=4.3 for LDHA and FC=27.2 for
315 PFKP); interestingly, the expression levels of both proteins were even higher in
316 cervical metastases than in HCE (FC= 10.4 and 42.7, respectively) see
317 Supplementary Table 7). This suggests that overexpression of LDHA and PFKP
318 could be an important factor not only for tumor progression but also for the
319 development of metastases. Interestingly, we reconfirmed that LDHA expression was
320 higher in patients who had died and/or had active disease than in those who were

321 cured or survived more than 5 years (see Figure 3A-E and 3K). In contrast, there
322 were not statistically significant differences in the PFKP expression between the
323 groups (See Figure 3F-3J).

324 **The LDHA and PFKP genes, at the mRNA or protein level, are good markers of**
325 **survival in CC**

326 At both the mRNA (n=58 CC) and protein (n=69) levels, we confirmed that the
327 overexpression of LDHA and PFKP caused a significant decrease in OS and DFS
328 during more than 5 years of follow-up; however, the results were stronger with the
329 analysis of proteins. The analysis of mRNA is shown in Supplementary Table 8 and
330 Figure 4A-C and 4G-I.

331 At the protein level, we found that the percentage of patients who survived decreased
332 markedly when LDHA or PFKP proteins were overexpressed compared to the group
333 in which these proteins were not overexpressed: 39% vs. 82% and 55% vs. 83%
334 (both $p < 0.05$, log-rank test), respectively (see Figure 4D and 4E). Similar results
335 were found when DFS was analyzed (Figure 4J and 4K). Interestingly, when both
336 proteins were overexpressed (LDHA+/PFKP+), OS and DFS decreased dramatically
337 to 29% and 23%, respectively; in contrast, when there was a single overexpressed
338 protein, the survival rate was 64% in patients with and without the active disease, and
339 when neither of these two proteins was expressed, the survival rate was 90% ($p = 1.0$
340 $\times 10^{-3}$ and $p = 9.2 \times 10^{-5}$, log-rank test; see Figure 4F and 4L).

341 With the univariate Cox analysis, the risk of dying was much higher with advanced
342 FIGO stages than with the overexpression of each of the two markers (Table 2).
343 However, when both markers were overexpressed, they confer a greater risk of death
344 than FIGO [HR =7 (95% CI 1.6-31.1, $p = 1.0 \times 10^{-2}$) versus HR=8.1 (95% CI=2.6-
345 26.1; $p = 4.3 \times 10^{-4}$]. Similar figures were seen for DFS (Table 2). Interestingly, in the

346 multivariate analysis, both genes remained, together with clinical stage, in the models
347 of OS or DFS, indicating that they confer a risk of death independent of FIGO stage,
348 even of similar magnitude or greater than that conferred by FIGO stage when both
349 markers are overexpressed [OS:HR= 6.1 (95% CI=1.3-31.2; $p=1.8 \times 10^{-2}$) vs. HR=
350 6.6 (95% CI=1.3-32.1; $p=2.5 \times 10^{-2}$) and [DFS:HR= 4.8 (95% CI=1.3-17.8; $p=1.8 \times$
351 10^{-2}) vs. HR=5.1 (95% CI=1.5-16.6; $p=7.0 \times 10^{-3}$)]. In fact, the HR increased
352 exponentially as the level of expression of these markers increased, especially that of
353 LDHA (Figure 2E). In 5 patients, the HR was well above the average HR of 4,
354 reaching an HR value of 12.6 in the patient with an LDHA intensity of 83,538 OD
355 units.

356

357 **4. Discussion**

358 This is the first study in which it was identified that the overexpression of the LDHA
359 and PFKP genes of the glycolysis pathway, both at the mRNA and protein levels, are
360 good prognostic markers for OS and DFS in patients with CC, independent of FIGO
361 stage. In fact, the risk of death when these two markers are elevated is equal to or
362 greater than that of FIGO stage and increases exponentially with the protein level in
363 the tumor, especially LDHA.

364 LDHA is part of the enzyme lactate dehydrogenase (LDH), which converts pyruvate
365 into lactate. This enzyme is composed of 4 subunits, which can be A (LDHA), B
366 (LDHB) or a combination of both [22]. Previous studies have shown that the isoforms
367 in which the A subunit predominates favor the conversion of pyruvate into lactate,
368 which stimulates glycolysis instead of oxidative phosphorylation. In contrast, when
369 the B subunit predominates, the reverse happens: lactate is converted to pyruvate
370 and metabolized by the Krebs/oxidative phosphorylation cycle [23]. In this work, we
371 show that in CC, subunit A is overexpressed, which indicates that LDHA favors the

372 production of lactate and, with it, anaerobic metabolism, which can provide growth
373 advantages to CC. On the other hand, PFKP, an isoform of the enzyme
374 phosphofructokinase 1 (PFK-1), stimulates the activity of glycolysis by catalyzing the
375 formation of fructose 1,6-bisphosphate from fructose 6-phosphate, the first rate-
376 limiting step of glycolysis, and consequently the production of pyruvate. The
377 simultaneous overexpression of PFKP and LDHA makes sense for the tumor,
378 because the concerted action of the two enzymes in CC could rapidly metabolize
379 pyruvate to lactate, producing an acceleration of glycolysis (10-100 times faster than
380 total glucose oxidation in the mitochondria), achieving a large amount of anaerobic
381 ATP. This favors tumor growth and the development of more aggressive invasive
382 tumors.

383 No studies have assessed the influence of LDHA gene expression on the
384 aggressiveness and survival of patients with CC. A couple of studies focused on
385 LDHA as a part of the tumor gene expression profile associated with metastases [24]
386 and resistance to chemotherapy [25], however, with contradictory results. In the
387 profile associated with resistance to chemotherapy, the LDHA gene was upregulated,
388 while in the profile associated with tumor metastases, the LDHA gene was
389 downregulated. Interestingly, in this last study, tumors FIGO stage \leq IIB
390 predominated, while in the first study, tumors FIGO stage \geq IIB predominated. This
391 could suggest that in tumors of greater clinical stage and larger size in which hypoxia
392 probably already exists, anaerobic metabolism predominates, while in early stages
393 with smaller tumor sizes, aerobic metabolism predominates.

394 On the other hand, several studies have shown that increased serum LDH activity in
395 patients with CC was associated with poor prognosis and decreased OS [26] and
396 DFS [27], with an increased risk of death or recurrence, independent of other clinical
397 factors [28]. However, the limitation of these studies was that they did not

398 demonstrate whether the quantified LDH levels came specifically from CC or from
399 other tissues, since this enzyme is produced in several tissues.

400 In several types of tumors (such as squamous cell carcinoma of the skin and
401 melanoma), increased expression of glycolysis genes is associated with increased
402 tumor progression and decreased survival time in patients [29]. In addition, in many
403 types of cancers, it has been observed through PET using fluorodeoxyglucose (FDG)
404 that increased tumor glucose consumption is related to tumor aggressiveness [30].
405 This phenomenon has also been demonstrated in animal models. For example, in
406 two mouse models of triple-negative breast cancer (TNBC), 4T1 and Py8119,
407 inhibition of glycolysis resulted in reduced tumor growth and metastases, which
408 prolonged mouse survival [31]. In CC cell lines, LDHA silencing has been shown to
409 decrease some neoplastic features *in vitro*. For example, HeLa and SiHa cells
410 decreased colony formation and invasion capacity when the gene is silenced by miR-
411 34a. Interestingly, when the activity of miRNA was finished, the activity of LDHA was
412 reactivated at baseline levels favoring cell proliferation and invasion, demonstrating
413 the importance of the expression of this gene for the tumor neoplastic phenotype
414 [32].

415 Considering the importance of the neoplastic phenotype and tumor metabolism,
416 LDHA could be a promising therapeutic target in CC. Several pharmacological
417 inhibitors for LDHA have previously been reported for use in cancer, and there are
418 currently several studies looking for more selective inhibitors [33] [34]. One of these
419 compounds, gossypol, is being used in clinical trials for the treatment of malignant
420 glioma (NCT00540722 and NCT00390403).

421 Although there are no PFKP reports in CC, this enzyme has been found to be
422 overexpressed in HeLa cells [35] and related to the activation of tumor survival
423 pathways via P44/42 mitogen-activated protein kinase (MAPK) [36]. Increased PFKP

424 expression and activity are related to neoplastic activity, metastasis production, and
425 decreased survival in several types of cancer, primarily brain, kidney, and breast
426 cancers [37] , [38]. Other studies have shown that the inhibition of PFKP with specific
427 siRNAs in lung cancer cell lines [37] and murine tumor models of leukemia [39]
428 decreased the expression of the enzyme and glycolysis, glucose, lactic acid and ATP
429 concentrations in the supernatant of cell cultures, as well as tumor growth and
430 progression.

431 Simultaneous overexpression of PFKP and LDHA has previously been described in
432 breast cancer cell lines (MDA-MB-231), in which PFKP regulation also regulates
433 lactate production. Interestingly, quercetin treatment impaired PFKP-LDHA signaling
434 axis thereby inhibiting aerobic glycolysis and migration and cell invasion *in vitro* by
435 80% [38], demonstrating that inhibition of both enzymes may be useful in the
436 treatment of cancers in which these enzymes are activated, as in CC.

437 **5. Conclusions**

438 The overexpression of the glycolytic enzymes Lactate dehydrogenase A (LDHA) and
439 phosphofructokinase platelet (PFKP) was associated with poor overall and disease-
440 free survival in CC. Overexpression of LDHA and PFKP genes increased the risk of
441 death from CC by 8 times, and this effect was independent of the FIGO clinical stage.
442 In fact, the risk of death from CC increased exponentially as the expression level of
443 these markers, mainly LDHA, increased. The measurement of gene expression of
444 these two markers could be very useful to evaluate the clinical evolution and the risk
445 of death from CC and to make better therapeutic decisions at the beginning of
446 treatment.

447 **6. Abbreviations**

448 ADPGK: ADP-dependent glucokinase; ALDOA: aldolase; AUC: area under the curve;
449 CC: cervical cancer; DFS: disease-free survival; EDARADD: EDAR-associated death

450 domain; ENO1: enolase 1; FIGO: International Federation of Gynecology and
451 Obstetrics; FC: fold change; GPI: glucose-6-phosphate isomerase; GAPDH:
452 glyceraldehyde-3-phosphate dehydrogenase; HG-CIN: high-grade cervical
453 intraepithelial neoplasia; HK2: hexokinase 2; HR: hazard ratio; IH:
454 immunohistochemistry; LDHA: lactate dehydrogenase A; OS: overall survival; PFKP:
455 phosphofructokinase platelet; PGK1: phosphoglycerate kinase; PKM pyruvate kinase
456 M; qRT-PCR: quantitative real-time-polymerase chain reaction; SLC2A1: solute
457 carrier family 2 member 1; SLC9A1: solute carrier family 9 member A1; TP1P1:
458 triosephosphate isomerase 1 pseudogene 1; WB: Western blotting.

459 **Declarations**

460 **7. Ethics approval and consent to participate**

461 The study protocol was approved by the Scientific and Ethics Committee of the
462 General Hospital of Mexico (HGM) (approval number DIC/03/311/04/051). This study,
463 all experiments and analyses were performed in accordance with the Declaration of
464 Helsinki. Written informed consent was obtained from all participants before their
465 inclusion in the study.

466

467 **8. Consent for publication**

468 Not applicable.

469

470 **9. Availability of data and materials**

471 The datasets GSE52904 and GSE39001 analyzed during the current study are
472 available in the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) and are
473 available in the NCBI-GEO repository.

474 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52904>

475 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39001>

476

477

478 **10. Competing interests**

479 All authors have completed the ICMJE uniform disclosure form at
480 www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for
481 the submitted work; no financial relationships with any organizations that might have
482 an interest in the submitted work in the previous three years; no other relationships or
483 activities that could appear to have influenced the submitted work.

484

485 **11. Funding**

486 This research was conducted with support from the National Council on Science and
487 Technology (Conacyt) under grant numbers 8135/A1, 24341 (to JB) and Laboratorio
488 Huella Génica.

489 **12. Author contributions**

490 Study concept and design: J.B. and V.B.S. Performed the experiments: V.B.S.,
491 A.G.C., A.M.E., I.M.M., A.A., and E.J. Analyzed the data and wrote the manuscript:
492 V.B.S and J.B. Contributed reagents/materials: O.F.H., N.V.S. Analyzed and
493 interpreted the image data: M.G.Z. Clinically evaluated CC patients: E.R.B.,
494 M.E.S.N., S.B.M. Provided cervical specimens from these patients: E.R.B., S.B.M. All
495 authors read and approved the manuscript. All authors gave final approval of the
496 version to be published.

497

498 **13. Acknowledgments**

499 This study was performed as part of the requirements needed to obtain the Ph.D.
500 degree of VB from Programa de Posgrado en Ciencias Biológicas, Universidad
501 Nacional Autónoma de México (UNAM) and received a fellowship from CONACYT

502 (487890). We thank Dr. Valeria Barrón and Biologist Anabell Alvarado for training in
503 some laboratory techniques.

504 **8. References**

505 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.
506 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
507 Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*.
508 2021; 71:209–49.

509 2. Zhu Y, Wang Y, Hirschhorn J, Welsh KJ, Zhao Z, Davis MR, et al. Human
510 Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination.
511 In: *Advances in Clinical Chemistry*. Academic Press Inc.; 2017. p. 135–92.

512 3. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N.
513 Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and
514 follow-up. *Annals of Oncology*. 2017;28:iv72–83.

515 4. Friedlander M, Grogan M. Guidelines for the Treatment of Recurrent and
516 Metastatic Cervical Cancer. *The Oncologist*. 2002;7:342–7.

517 5. Yoshida K, Kajiyama H, Utsumi F, Niimi K, Sakata J, Suzuki S, et al. A post-
518 recurrence survival-predicting indicator for cervical cancer from the analysis of 165
519 patients who developed recurrence. *Molecular and Clinical Oncology*. 2017.
520 <https://doi.org/10.3892/mco.2017.1530>.

521 6. Duyn A, van Eijkeren M, Kenter G, Zwinderman K, Ansink A. *Acta Obstetrica et*
522 *Gynecologica Scandinavica* Recurrent cervical cancer: detection and prognosis. *Acta*
523 *Obstet Gynecol Scand*. 2002; 81:351–5.

- 524 7. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM,
525 Funkhouser WK, et al. Molecular biomarkers for the evaluation of colorectal cancer:
526 Guideline from The American Society for Clinical Pathology, College of American
527 Pathologists, Association for Molecular Pathology, and the American Society of
528 Clinical Oncology. *Journal of Clinical Oncology*. 2017; 35:1453–96.
- 529 8. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-
530 Angulo AM, et al. Use of biomarkers to guide decisions on systemic therapy for
531 women with metastatic breast cancer: American Society of Clinical Oncology clinical
532 practice guideline. *Journal of Clinical Oncology*. 2015; 33:2695–704.
- 533 9. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nature*
534 *Reviews Cancer*. 2004; 4:891–9.
- 535 10. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in
536 24 cancer classes. *Genomics*. 2004; 84:1014–20.
- 537 11. Huang X-Q, Chen X, Xie X-X, Zhou Q, Li K, Li S, et al. Co-expression of CD147
538 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous
539 cell carcinoma. *Int J Clin Exp Pathol*. 2014; 7:1651–66.
- 540 12. Huang X, Liu M, Sun H, Wang F, Xie X, Chen X, et al. Original Article HK2 is a
541 radiation resistant and independent negative prognostic factor for patients with locally
542 advanced cervical squamous cell carcinoma. 2015.
- 543 13. Cai L, Hu C, Yu S, Liu L, Yu X, Chen J, et al. Identification and validation of a six-
544 gene signature associated with glycolysis to predict the prognosis of patients with
545 cervical cancer. *BMC Cancer*. 2020;20.

- 546 14. Scher N, Castelli J, Depeursinge A, Bourhis J, Prior JO, Herrera FG, et al. (18F)-
547 FDG PET/CT parameters to predict survival and recurrence in patients with locally
548 advanced cervical cancer treated with chemoradiotherapy. *Cancer/Radiotherapie*.
549 2018; 22:229–35.
- 550 15. Ke X, Shen L. Molecular targeted therapy of cancer: The progress and future
551 prospect. *Frontiers in Laboratory Medicine*. 2017; 1:69–75.
- 552 16. Medina-Martinez I, Barrón V, Roman-Bassaure E, Juárez-Torres E, Guardado-
553 Estrada M, Espinosa AM, et al. Impact of gene dosage on gene expression,
554 biological processes and survival in cervical cancer: A genome-wide follow-up study.
555 *PLoS ONE*. 2014;9.
- 556 17. Riis P. Thirty years of bioethics: the Helsinki Declaration 1964-2003. *New Rev*
557 *Bioeth*. 2003;1:15–25.
- 558 18. Espinosa AM, Alfaro A, Roman-Basaure E, Guardado-Estrada M, Palma Í,
559 Serralde C, et al. Mitosis Is a Source of Potential Markers for Screening and Survival
560 and Therapeutic Targets in Cervical Cancer. *PLoS ONE*. 2013;8.
- 561 19. Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et
562 al. Revised FIGO staging for carcinoma of the cervix uteri. *International Journal of*
563 *Gynecology and Obstetrics*. 2019; 145:129–35.
- 564 20. Ruifrok AC, Katz RL, Johnston A. Comparison of Quantification of Histochemical
565 Staining By Hue-Saturation-Intensity (HSI) Transformation and Color-Deconvolution.
566 2003.
- 567 21. Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic
568 curves. *Acta Paediatrica, International Journal of Paediatrics*. 2007; 96:644–7.

- 569 22. Kopperschliger G, Kirchberger J. Methods for the separation of lactate
570 dehydrogenases and clinical significance of the enzyme. 1996.
- 571 23. Draoui N, Feron O. Lactate shuttles at a glance: From physiological paradigms to
572 anti-cancer treatments. *DMM Disease Models and Mechanisms*. 2011;4:727–32.
- 573 24. Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP, et al. Identification of
574 a gene-expression signature for predicting lymph node metastasis in patients with
575 early stage cervical carcinoma. *Cancer*. 2011;117:3363–73.
- 576 25. An JS, Huang MN, Song YM, Li N, Wu LY, Zhan QM. A preliminary study of
577 genes related to concomitant chemoradiotherapy resistance in advanced uterine
578 cervical squamous cell carcinoma. *Chinese Medical Journal*. 2013;126:4109–15.
- 579 26. Wang H, Wang M sen, Zhou YH, Shi JP, Wang WJ. Prognostic values of LDH
580 and CRP in cervical cancer. *OncoTargets and Therapy*. 2020;13:1255–63.
- 581 27. Wang WJ, Li Y, Zhu J, Gao MJ, Shi JP, Huang YQ. Prognostic Values of
582 Systemic Inflammation Response (SIR) Parameters in Resectable Cervical Cancer.
583 Dose-Response. 2019;17.
- 584 28. Li J, Wu MF, Lu HW, Chen Q, Lin ZQ, Wang LJ. Pretreatment serum lactate
585 dehydrogenase is an independent prognostic factor for patients receiving
586 neoadjuvant chemotherapy for locally advanced cervical cancer. *Cancer Medicine*.
587 2016;5:1863–72.
- 588 29. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al.
589 Overexpression of Glut-1 and increased glucose metabolism in tumors are
590 associated with a poor prognosis in patients with oral squamous cell carcinoma.
591 *Cancer*. 2003;97:1015–24.

- 592 30. Gambhir SS. Molecular imaging of cancer with positron emission tomography.
593 Nature Reviews Cancer. 2002;2:683–93.
- 594 31. Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic Glycolysis Controls
595 Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB
596 Isoform in Triple-Negative Breast Cancer. Cell Metabolism. 2018;28:87-103.e6.
- 597 32. Zhang R, Su J, Xue S-L, Yang H, Ju L-L, Ji Y, et al. HPV E6/p53 mediated down-
598 regulation of miR-34a inhibits Warburg effect through targeting LDHA in cervical
599 cancer. 2016.
- 600 33. Jafary F, Ganjalikhany MR, Moradi A, Hemati M, Jafari S. Novel Peptide
601 Inhibitors for Lactate Dehydrogenase A (LDHA): A Survey to Inhibit LDHA Activity via
602 Disruption of Protein-Protein Interaction. Scientific Reports. 2019;9.
- 603 34. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. The Regulation and Function
604 of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor. Brain Pathology.
605 2016;26:3–17.
- 606 35. Moreno-Sánchez R, Marín-Hernández A, Gallardo-Pérez JC, Quezada H,
607 Encalada R, Rodríguez-Enríquez S, et al. Phosphofructokinase type 1 kinetics,
608 isoform expression, and gene polymorphisms in cancer cells. Journal of Cellular
609 Biochemistry. 2012;113:1692–703.
- 610 36. Cardim Pires TR, Albanese JM, Schwab M, Murette A, Carvalho RS, Sola-Penna
611 M, et al. Phosphofructokinase-P Modulates P44/42 MAPK Levels in HeLa Cells.
612 Journal of Cellular Biochemistry. 2017;118:1216–26.
- 613 37. Shen J, Jin Z, Lv H, Jin K, Jonas K, Zhu C, et al. PFKP is highly expressed in
614 lung cancer and regulates glucose metabolism. Cellular Oncology. 2020;43:617–29.

615 38. Umar SM, Kashyap A, Kahol S, Mathur SR, Gogia A, Deo SVS, et al. Prognostic
616 and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast
617 cancer. *Experimental Cell Research*. 2020;396.

618 39. Qing Y, Dong L, Gao L, Li C, Li Y, Han L, et al. R-2-hydroxyglutarate attenuates
619 aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. *Molecular*
620 *Cell*. 2021;81:922-939.e9.

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657 **Figure legends**

658

659 **Figure 1. Unsupervised hierarchical cluster analysis of 14 glycolytic genes in**

660 **CC.** The segregation of HCE (n=17), HG-CINs (n=10) and CC (n=76) is shown
661 according to the expression profile of 14 glycolytic genes. Four groups were
662 distinguished: the first group with downregulation of the genes (Group 1), the second
663 and third groups (Groups 2A and 2B) with intermediate expression levels, and the
664 fourth group with an upregulation profile (Group 3). Each column represents a
665 sample, and each line represents a glycolytic gene. The number at the end of the CC
666 sample name (1 to 4) indicates the FIGO I, II, III, and IV stages of the patient. The
667 length and subdivision of the arms represent the relationship between the samples
668 based on the intensity of gene expression: red for upregulation, blue for
669 downregulation, and white for no change in expression. The analysis was performed
670 with the expression values expressed in logarithmic form (base 2).

671 **Figure 2. Validation of LDHA and PFKP expression in CC.** The expression of

672 LDHA and PFKP in CC was validated at the mRNA and protein levels by qRT-PCR
673 and WB, respectively. Panel A shows the qRT-PCR analysis of LDHA and PFKP
674 mRNA in 58 CCs. The expression was normalized with respect to the internal control
675 (RPS13) and the control group by the double delta method using the final formula ($2^{-\Delta\Delta CT}$).
676 Panels B and C show representative images of WB of LDHA and PFKP
677 expression, respectively: surviving patients, nonsurviving patients, no recurrence
678 patients and recurrence patients. The molecular weight of the proteins is shown in
679 kilodaltons (kDa). The protein β -actin was used as an internal control. Panel D show
680 the mean expression \pm SD of LDHA and PFKP proteins between patients with CC
681 who survived (white bars, n=47) vs. those who died (gray bars, n=22). The intensity
682 of LDHA and PFKP was normalized with respect to β -actin. The expression is shown
683 as optical density (OD) units. The significant differences between the groups were

684 calculated with the Mann–Whitney U test, and $p < 0.05$ was considered statistically
685 significant. Panel E shows the hazard ratio (HR) analysis in relation to LDHA and
686 PFKP protein expression in CC. The risk of dying from CC increases exponentially as
687 protein expression (OD) increases, but it is more evident with the expression of
688 LDHA (dark blue circles represent nonsurviving patients, while light blue circles
689 represent surviving patients) than PFKP (dark red circles represent nonsurviving
690 patients, while light red circles represent surviving patients).SD= standard deviation.

691 **Figure 3. Expression of LDHA and PFKP proteins by IH.** The expression of the
692 LDHA and PFKP proteins was determined by immunohistochemistry (IH) and
693 compared between patients who survived without the disease (No recurrence) and
694 patients who died and/or remained with the disease (Recurrence). Histological
695 analysis included 12 controls, 18 CC and 6 metastatic tissues. Panels A-E show the
696 detection of the LDHA protein, and panels F-J show the detection of the PFKP
697 protein with a specific antibody. A representative image of the experiments is shown.
698 The specific signal for proteins is shown in brown color and counterstained with
699 hematoxylin in violet color. Original amplification 400x; the bars measure 20 μ m.
700 Panels K show the quantitative analysis of LDHA and PFKP expression in CC tissues
701 of patients No recurrence vs recurrence determined by IH. The average optical
702 density and staining area of LDHA and PFKP (DOI) in the tissues were considered.
703 The mean \pm SD of three independent experiments is shown. Mann–Whitney test was
704 performed to assess the difference between the groups, and $p < 0.05$ was
705 considered statistically significant. SD= standard deviation.

706 **Figure 4. Kaplan–Meier survival curves of LDHA and PFKP.** OS analysis and
707 according to the expression of LDHA and PFKP by qRT–PCR (panels A-C) and WB
708 (panels D-F). DFS analysis according to the expression of LDHA and PFKP by qRT–
709 PCR (panels G-I) and WB (panels J-L). The cutoff values were calculated using ROC

710 curves. In the overall survival analysis, the red lines include the values of
711 nonsurviving patients, while the blue line includes the values of surviving patients. In
712 the disease-free survival analysis, the red lines contain the values of nonsurviving
713 patients and surviving patients with the disease, while the blue lines include the
714 values of surviving cured patients. Censored patients are shown marked with vertical
715 bars. The p value was calculated with the log-rank test.

716 **Supplementary Figure 1. Analysis workflow of 188 cervical cancer cases.** Figure
717 shows the analysis workflow of the 188 CC cases explored in this study. The
718 expression of 14 genes involved in glycolysis were investigated in 76 CC with HG-
719 1.0ST microarray and 9 genes were explored in 42 CC with HG-Focus, with 21 CCs
720 in common. Five-year survival was investigated in 61 of 76 patients with CC explored
721 with HG 1.0 ST and 36 of 42 patients investigated with HG-Focus. The expression of
722 the LDHA and PFKP was validated by qRT-PCR, WB and IH. All patients explored
723 by qRT-PCR (n=58) and 59 of 69 patients studied by WB were included in the follow-
724 up studies, with 15 CCs in common. The protein expression of LDHA and PFKP was
725 determined in 18 CC tissues by IH.

726 **Supplementary Figure 2. Expression of glycolytic genes in CC. Box plots of the**
727 **expression of 14 genes of the glycolytic pathway obtained with the HG-1.0ST**
728 **microarray.** The analysis was performed on 17 controls, 10 HG-CIN patients and 76
729 CC patients. The graphs show the value of the normalized fluorescence intensity (log
730 2) for each gene. The upper and lower limits of the boxes represent the 75th and 25th
731 percentiles, respectively. The mean is shown as the center black line inside the
732 boxes, and the median is shown as "+". The whiskers represent the maximum and
733 minimum values that lie within 1.5 times the interquartile range from the ends of the
734 frame. Values outside this range are displayed as black dots. The *Mann-Whitney U*

735 *test* was used to determine the significant differences between the groups, $**p < 0.05$,
736 $*** p < 0.005$.

737 **Supplementary Figure 3. Box plots of the expression of 9 genes of the**
738 **glycolytic pathway obtained with the HG-Focus microarray.** The analysis was
739 performed on 12 controls and 76 CC16+ patients. The graphs show the value of the
740 normalized fluorescence intensity (log 2) for each gene. The upper and lower limits of
741 the boxes represent the 75th and 25th percentiles, respectively. The mean is shown
742 as the center black line inside the boxes, and the median is shown as "+". The
743 whiskers represent the maximum and minimum values that lie within 1.5 times the
744 interquartile range from the ends of the frame. Values outside this range are
745 displayed as black dots. The *Mann–Whitney U test* was used to determine the
746 significant differences between the groups, $**p < 0.05$, $*** p < 0.005$.

747 **Supplementary Figure 4. Unsupervised hierarchical cluster analysis of 9**
748 **glycolytic genes in CC.** The segregation of 12 controls and 42 CC HPV16+ is
749 shown according to the expression profile of 9 glycolytic genes explored with the HG-
750 Focus microarray, and 4 groups were distinguished: a first group with downregulation
751 of the genes (Group 1), the second and third groups (Groups 2A and 2B) with
752 intermediate expression levels and the fourth group with an upregulation profile
753 (Group 3). Each column represents a sample, and each line represents a glycolytic
754 gene. The number at the end of the CC sample name (1 to 4) indicates the FIGO I, II,
755 III, and IV stages of the patient. The length and subdivision of the arms represent the
756 relationship between the samples based on the intensity of gene expression: red for
757 upregulation, blue for downregulation, and white for no change in expression. The
758 analysis shows gene expression in log 2.

759

760 **Supplementary Figure 5.** Kaplan–Meier survival curves of HG-1.0 ST microarray.
761 The OS (A–I panels) and DFS (J–O panels) of patients with CC were analyzed
762 according to the expression of the 14 glycolytic genes obtained with the HG-1.0ST
763 microarray using the Kaplan–Meier method with the SPSS program. The cutoff
764 values of the expression of each gene that best separated the women were
765 calculated using ROC curves. In the overall survival analysis, the red lines include
766 the values of nonsurviving patients, while the blue line includes the values of
767 surviving patients. In the disease-free survival analysis, the red lines contain the
768 values of nonsurviving patients and surviving patients with the disease, while the blue
769 lines include the surviving cured patients. The mean follow-up time of patients 60
770 months after the initial diagnosis. Censored patients are shown marked with vertical
771 bars. The *p value* was calculated with the log-rank test.

772 **Supplementary Figure 6. Kaplan–Meier survival curves.** The OS (A–J panels) and
773 DFS (K panel) of patients with CC were analyzed according to the expression of the
774 9 glycolytic genes obtained with the HG-Focus microarray using the Kaplan–Meier
775 method. The cutoff values of the expression of each gene that best separated the
776 patients were calculated using ROC curves. In the overall survival analysis, the red
777 lines include the values of nonsurviving patients, while the blue line includes the
778 values of surviving patients. In the disease-free survival analysis, the red lines
779 contain the values of nonsurviving patients and surviving patients with the disease,
780 while the blue lines include the values of surviving cured patients. Censored patients
781 are shown marked with vertical bars. The *p value* was calculated with the log-rank
782 test.

783
784
785
786
787
788

789

790

791

Table 1. Univariate and multivariate analyses for the overall survival of patients with CC with Cox proportional hazards models including the expression of glycolytic genes explored with HG 1.0 ST microarray and FIGO clinical stage.

Covariates	n	Univariate analysis ^e			Multivariate analysis ^f		
		HR ^b	95% CI	p ^c	HR ^b	95% CI	p ^c
FIGO							
≤IIA	29	1			1.0		
≥IIB	32	3.4	1.1-10.4	3.6×10^{-2}	3.3 ^d	1.1-9.6 ^d	3.5×10^{-2d}
LDHA							
Low ^a	40	1.0			1.0		
High	21	3.1	1.1-8.3	2.7×10^{-2}	3.0	1.1-8.19	2.9×10^{-2}
PFKP							
Low	32	1.0			1.0		
High	29	3.5	1.1-10.9	3.0×10^{-2}	3.4	1.1-10.5	3.5×10^{-2}
TPI1P1							
Low	52	1.0			1.0		
High	9	3.7	1.3-10.9	1.5×10^{-3}	2.6	0.8-7.87	4.0×10^{-2}
GAPDH							
Low	54	1.0			1.0		
High	7	5.6	1.9-16.3	2.0×10^{-3}	4.0	1.3-12.3	5.2×10^{-2}
GPI							
Low	19	1.0			1.0		
High	42	8.5	1.1-64.1	3.9×10^{-2}	7.9	1.0-60.0	5.6×10^{-2}
ENO							
Low	21	1.0			1.0		
High	40	9.2	1.2-69.5	3.2×10^{-2}	7.3	0.9-56.4	5.6×10^{-2}
PGK1							
Low	44	1.0			1.0		
High	17	2.8	1.0-7.6	3.7×10^{-2}	2.3	0.9-6.2	1.1×10^{-1}
ALDOA							
Low	15	1.0			1.0		
High	46	5.8	0.7-44.3	8.7×10^{-2}	4.9	0.6-37.6	1.2×10^{-1}

792

CI= confidence interval; HR= hazard ratio; FIGO stage=International Federation of Gynecology and Obstetrics stage.

793

794

a. Optimal cutoff values were selected according to the ROC analysis in relation to fold changes in genes expression obtained with the Human Gene 1.0 ST microarray.

795

796

b. Adjusted hazard ratio.

797

c. Cox proportional hazards model.

798

d. These calculations were obtained in the multivariate analysis performed with LDHA. The values of FIGO obtained in the multivariate analysis with the other markers are not shown but are similar to these values.

799

800

e. Univariate analysis was performed considering one variable for the analysis.

801

f. Multivariate analysis was performed considering gene expression and FIGO stage for the analysis.

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817 **Table 2.** Hazard ratio analyses of patients with CC with Cox proportional hazards
 818 models including the expression of the glycolytic proteins LDHA and PFKP and FIGO
 819 clinical stage

Covariates	Univariate analysis ^e				Multivariate analysis ^f		
	n	HR ^c	95% CI	p ^d	HR ^c	95% CI	p ^d
Overall Survival							
LDHA							
FIGO \leq IIA ^a	27	1			1		
FIGO \geq IIB	32	7.0	1.6-31.3	1.0 X 10 ⁻²	5.5	1.2-25.2	2.7 x 10 ⁻²
Low ^b	43	1			1		
High	16	4	1.4-11.1	8.0 X 10 ⁻³	2.8	1.0-7.9	5.2 x 10 ⁻²
PFKP							
FIGO \leq IIA ^a	27	1			1		
FIGO \geq IIB	32	7.0	1.6-31.3	1.0 X 10 ⁻²	6.9	1.5-30.5	1.1 x 10 ⁻²
Low ^b	33	1			1		
High	26	3.3	1.1-10.55	4.0 X 10 ⁻²	3.2	1.0-10.2	4.6 x 10 ⁻²
LDHA/PFKP ^g							
FIGO \leq IIA ^a	27	1			1		
FIGO \geq IIB	32	7.0	1.6-31.3	1.0 X 10 ⁻²	6.1	1.3-31.2	1.8 x 10 ⁻²
Low ^b	23	1			1		
One high	25	2.2	0.65-7.6	2.0 x 10 ⁻¹	5.3	1.0-25.6	4.0 x 10 ⁻²
Two high	11	8.1	2.6-26.10	4.3 x 10 ⁻⁴	6.6	1.3-32.1	2.5 x 10 ⁻²
Disease-free survival							
LDHA							
FIGO \leq IIA ^a	27	1			1		
FIGO \geq IIB	32	6.4	1.9-21.7	3.0 X 10 ⁻³	4.6	1.3-16.2	1.7 x 10 ⁻²
Low ^b	43	1			1		
High	16	4.5	1.9-10.8	1.0 X 10 ⁻³	3.2	1.3-7.6	1.2 x 10 ⁻²
PFKP							
FIGO \leq IIA ^a	27	1			1		
FIGO \geq IIB	32	6.4	1.9-21.7	3.0 X 10 ⁻³	6.1	1.7-20.6	4.0 x 10 ⁻²
Low ^b	28	1			1		
High	31	3.2	1.2-8.2	1.8 X 10 ⁻²	2.9	1.1-7.5	2.8 x 10 ⁻²
LDHA/PFKP ^g							
FIGO \leq IIA ^a	27	1			1		
FIGO \geq IIB	32	6.4	1.9-21.7	3.0 X 10 ⁻³	4.8	1.3-17.9	1.8 x 10 ⁻²
Low ^b	23	1			1		
One high	25	2.2	0.7-7.6	2.0 x 10 ⁻¹	2.7	0.8-9.5	1.1 x 10 ⁻¹
Two high	11	8.1	2.5-26.1	4.3 x 10 ⁻⁴	5.1	1.5-16.6	7.0 x 10 ⁻³

820 a. FIGO stage analysis

821 b. Optimal cutoff values were selected according to the ROC analysis in relation to the expression of LDHA or
 822 PFKP obtained with WB.

823 c. Adjusted hazard ratio.

824 d. Cox proportional hazards model.

825 e. Univariate analysis was performed considering one variable for the analysis.

826 f. Multivariate analysis was performed considering gene expression and FIGO stage for the analysis.

827 g. Low= downregulation of two genes; One high= upregulation of one gene; Two high= upregulation of LDHA and
 828 PFKP.

829 CI= confidence interval; HR = hazard ratio; FIGO stage= International Federation of Gynecology and Obstetrics
 830 stage

831

832


833

834


835

836

837



CC253-2
 C1N006
 HCE033
 CC456-2
 CC466-1
 CC102-1
 CC124-1
 CC075-1
 CC271-2
 CC323-3
 CC469-4
 C1N002
 HCE041
 HCE010
 HCE007
 CC221-1
 HCE036
 C1N012
 HCE038
 CC478-1
 HCE039
 C1N377
 HCE019
 CC087-1
 CC330-1
 CC268-2
 HCE024
 CC339-1
 HCE013
 HCE011
 HCE012
 HCE021
 C1N350
 CC313-3
 CC163-1
 CC230-1
 CC244-2
 CC322-3
 CC265-1
 HCE043
 CC116-1
 HCE005
 HCE020
 CC437-2
 CC121-1
 HCE045
 CC457-3
 C1N042
 C1N334
 C1N016
 C1N015
 C1N018
 CC495-2
 CC412-1
 CC426-2
 CC486-1
 CC189-1
 CC248-1
 CC298-3
 CC156-3
 CC154-3
 CC157-4
 CC386-1
 CC336-1
 CC081-1
 CC274-1
 CC462-4
 CC369-1
 CC468-1
 CC326-2
 CC444-2
 CC256-2
 CC345-2
 CC476-1
 CC307-2
 CC483-4
 CC494-3
 CC365-3
 C1N194-2
 CC158-4
 CC409-1
 CC455-2
 CC260-2
 CC072-1
 CC378-1
 CC411-3
 CC240-3
 CC315-3
 CC390-1
 CC489-3
 CC208-1
 CC392-3
 CC425-1
 CC282-3
 CC388-3
 CC496-3
 CC198-3
 CC458-2
 CC487-2
 C6K7-2
 CC035-1
 CC380-3
 CC326-2
 SiHa
 CC324-1
 HeLa







SLC2A1
 ADPGK
 ALDOA
 EDARADD
 ENO1
 GAPDH
 GPI
 HK2
 LDHA
 PFKP
 PGK1
 PKM
 TPI1P1
 SLC9A1

Group 1

Group 2A

Group 2B

Group 3

A**B****C****D****E**